Please assess the completion status of the following clinical trial:

Trial Title: IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed adrenocortical carcinoma~  * Documented unresectable recurrent, unresectable advanced, or metastatic disease~* At least 1 lesion that can be accurately measured by RECIST criteria as ≥ 20 mm by conventional radiologic techniques or as ≥ 10 mm by spiral CT scan or MRI~  * Patients with disease in an irradiated field as the only site of measurable disease allowed provided there has been a clear progression of the lesion~* No tumors potentially resectable by surgical excision alone~* No known or suspected leptomeningeal disease or brain metastases~* ECOG performance status 0-2~* Life expectancy ≥ 12 weeks~* ANC ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 9 g/dL (transfusion allowed)~* Serum creatinine ≤ 1.5 times upper limit of normal (ULN) OR calculated creatinine clearance ≥ 60 mL/min~* AST or ALT ≤ 3 times ULN~* Total bilirubin ≤ 1.5 times ULN~* HbA1c \< 8 within the past 4 weeks~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after completion of study therapy~* Able to take oral medications~* No poor gastrointestinal absorption~* Patients with diabetes mellitus are eligible provided they meet all of the following criteria:~  * Blood glucose is normal (random glucose ≤ 150 mg/dL)~ * HgbA1c ≤ 8 within the past 4 weeks~ * On a stable dietary or therapeutic regimen for the past 2 months~* No active uncontrolled infection~* No severe disease or condition that, in the judgement of the investigator, would make the patient inappropriate for study participation, including, but not limited to:~  * Bleeding diathesis~ * Uncontrolled chronic kidney or liver disease~ * Uncontrolled diabetes~ * History of cardiac history~ * Myocardial infarction within the past 6 months~ * Congestive heart failure~ * Unstable angina pectoris~ * Cardiac arrhythmia~ * Uncontrolled hypertension~* No current malignancy or previous malignancy with a disease-free interval of \< 2 years at the time of diagnosis~  * Patients with adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or skin, or stage A low-grade prostate cancer are eligible~* No known hypersensitivity to monoclonal antibody therapy or mitotane~* No known HIV or hepatitis B or C infection~* No serious medical or psychiatric disorder that would interfere with patient safety or informed consent~* All significant toxic effects of prior surgery resolved to ≤ grade 1 according to NCI CTCAE v. 3.0 criteria~* Mitotane for \< 8 weeks prior to study entry AND tolerated it well~* No prior IGFR-directed therapy~* No prior systemic antitumor therapy (cytotoxic chemotherapy, biologic, immunotherapy, or targeted therapy)~  * Prior incomplete surgical resections or radiofrequency ablation or radiotherapy will not be considered as prior therapy provided measurable sites of disease remain~ * Prior adjuvant chemotherapy or mitotane will not be considered as prior antitumor therapy unless it was completed \< 6 months before study enrollment~* No prior radiotherapy to \> 20% of bone marrow~* More than 4 weeks since prior and no concurrent radiotherapy~  * Radiotherapy for palliation of symptoms related to metastases is permitted provided that it is \> 4 weeks from study initiation, and does not involve target/measureable lesions that are followed for drug treatment response evaluation~* No concurrent mitotane ≥ 8 weeks prior to study~* No concurrent tumor resection or tumor-directed surgery~* No other concurrent anticancer or investigational therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm II (Mitotane + IMC-A12) (Type: EXPERIMENTAL): Patients receive mitotane as in arm I and anti-IGF-1R recombinant monoclonal antibody IMC-A12 IV over 1 hour once every 2 weeks in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy